Orphan disease

Michigan State University Investigator Receives $2.1m to Study Existing Treatments for Select Rare Diseases

Oct 31, 2019 | Brain Cancer, Liver Cancer, Organ Failure, Orphan disease, Rare Diseases

Michigan State University (MSU) College of Medicine investigator Bin Chen just was awarded $2.1 million by the National Institutes of Health (NIH) to scour vast databases of existing drugs in a quest to treat orphan diseases. The investigative team received an...

FDA Clears IND for ABO-202 Gene Therapy Candidate for Infantile Batten Disease

May 24, 2019 | Infantile Batten Disease, Orphan disease, Rare Diseases

The FDA’s positive decision clears Abeona Therapeutics’ Investigatory New Drug Application (IND) to start a Phase I/2 trial. The studies will be conducted at infantile Batten disease global centers of excellence which include: University of Rochester Medical Center ...

Pfizer to Buy Rare Disease Portfolio Pipeline for $810 Million

May 14, 2019 | M&A, Orphan disease, Pfizer, Rare Diseases

Pfizer will buy Therachon Holding, a privately held, clinical-stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia and short bowel syndrome (SBS). The deal is worth up to $810 million. Key Terms $340...

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

159 WEST BROADWAY SUITE 200
SALT LAKE CITY, UT 84101

Michigan State University Investigator Receives $2.1m to Study Existing Treatments for Select Rare Diseases

FDA Clears IND for ABO-202 Gene Therapy Candidate for Infantile Batten Disease

Pfizer to Buy Rare Disease Portfolio Pipeline for $810 Million

Pin It on Pinterest